15 Results for "

Tim-3 inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "Tim-3 inhibitor" in MCE Product Catalog:

  • Targets Recommended:
2
2 Cited Publications
Cat. No.: HY-144088
CAS No.: 2380300-79-6
Purity:  98.86%
Synonyms: HPK1-IN-22
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology Cancer

ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139738
CAS No.: 2883237-04-3
Purity:  99.15%
Target:  

Tim3

Research Areas:  

Cancer

TIM-3-IN-1 (Compound 38) is a TIM-3 inhibitor that can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-163028
CAS No.: 459789-75-4
Target:  

Tim3

Research Areas:  

Cancer

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
loading...
    loading...
Cat. No.: HY-155175
CAS No.: 1113126-49-0
Purity:  98.93%
Target:  

Tim3 IFNAR

Research Areas:  

Cancer

TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P990821

Target:  

Tim3

Research Areas:  

Inflammation/Immunology

Anti-Mouse TIM-3 Antibody (RMT3-23) is a kind of rat-derived anti-mouse TIM-3 IgG2a antibody inhibitor. Anti-Mouse TIM-3 Antibody (RMT3-23) blocks Tim-3 binding to phosphatidylserine (PtdSer) and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1). Anti-Mouse TIM-3 Antibody (RMT3-23) inhibits phagocytosis of apoptotic cells in peritoneal exudate Mac1+ cells. Anti-Mouse TIM-3 Antibody (RMT3-23) can be used for the researches of inflammation and immunology, such as rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P991449

Target:  

PD-1/PD-L1 Tim3

Research Areas:  

Cancer

LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P990004

Target:  

Tim3

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
loading...
    loading...
Cat. No.: HY-159884
CAS No.: 328540-44-9
Target:  

Tim3 TNF Receptor IFNAR

Research Areas:  

Cancer

MG-T-19 is a potent small-molecule inhibitor targeting human TIM-3. MG-T-19 blocks the interactions between TIM-3 and its ligands such as phosphatidylserine, CEACAM1 and Galectin-9. MG-T-19 promotes the secretion of TNF-α and IFN-γ by peripheral blood mononuclear cells, and significantly enhances their ability to inhibit cancer cell proliferation. MG-T-19 can be used in studies related to acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-149916
CAS No.: 2922920-71-4
Target:  

Adenosine Receptor

Research Areas:  

Cancer

A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
loading...
    loading...
Cat. No.: HY-145240
CAS No.: 2573979-31-2
Research Areas:  

Infection Cancer

eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
loading...
    loading...
Cat. No.: HY-P990716
CAS No.: 2648346-74-9
Synonyms: AZD7789

Target:  

PD-1/PD-L1 Tim3

Research Areas:  

Inflammation/Immunology

Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .
loading...
    loading...
Cat. No.: HY-P992460

Target:  

Tim3

Research Areas:  

Cancer

SHR-1702 is a monoclonal antibody targeting TIM-3, which specifically binds to and blocks the TIM-3 signaling pathway. SHR-1702 restores the function of immune cells and inhibits the proliferation process of malignant cells. SHR-1702 is mainly used in relevant research on acute myeloid leukemia and myelodysplastic syndromes .
loading...
    loading...
Cat. No.: HY-P992342

Target:  

Tim3

Research Areas:  

Cancer

DCB-8 is a specific inhibitor targeting human TIM-3. DCB-8 regulates T cell function, enhances cytokine secretion, and inhibits tumor growth in disease animal models. DCB-8 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P992454

Target:  

Tim3

Research Areas:  

Cancer

S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
loading...
    loading...
Cat. No.: HY-P992366

Target:  

Galectin Tim3

Research Areas:  

Cancer

HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 + T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
loading...
    loading...
  • 1